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Antimalarial drug resistance remains a major obstacle in malaria control. Evidence from Southeast Asia shows that resistance
to artemisinin combination therapy (ACT) is inevitable. Ethnopharmacological studies have confirmed the efficacy of curcumin
against Plasmodium spp. Drug interaction assays between curcumin/piperine/chloroquine and curcumin/piperine/artemisinin
combinations and the potential of drug treatment to interfere with the ubiquitin proteasome system (UPS) were analyzed. In
vivo efficacy of curcumin was studied in BALB/c mice infected with Plasmodium chabaudi clones resistant to chloroquine and
artemisinin, and drug interactionswere analyzed by isobolograms. Subtherapeutic doses of curcumin, chloroquine, and artemisinin
were administered to mice, and mRNA was collected following treatment for RT-PCR analysis of genes encoding deubiquitylating
enzymes (DUBs). Curcumin was found be nontoxic in BALB/c mice. The combination of curcumin/chloroquine/piperine
reduced parasitemia to 37% seven days after treatment versus the control group’s 65%, and an additive interaction was revealed.
Curcumin/piperine/artemisinin combination did not show a favorable drug interaction in thismurinemodel ofmalaria. Treatment
ofmice with subtherapeutic doses of the drugs resulted in a transient increase in genes encodingDUBs indicatingUPS interference.
If curcumin is to join the arsenal of available antimalarial drugs, future studies exploring suitable drug partners would be of interest.
1. Introduction
Malaria remains a major cause of mortality and morbidity
especially in sub-Saharan Africa. Children under five and
pregnant women remain the most vulnerable groups afflicted
by this disease [1]. Control programs are strongly affected
by resistance to insecticides and to antimalarials, includ-
ing the recently implemented combination therapies with
artemisinin and its derivatives [2, 3]. Development of new
antimalarial drugs is necessary though expensive and time
consuming, and a number of potential antimalarials exist
either derived from plants or as new synthetic compounds
[4]. Parasite drug-resistance and its spread throughout the
world can develop quite rapidly (as exemplified by the drug
pyrimethamine/sulfadoxine) [4], and there is a need to
intensify the search for new antimalarial agents preferably
acting on newer targets. Curcumin, the active compound
derived from the plant Curcuma longa, has anticancer, anti-
inflammatory, antiviral, and antimalarial activity [5–10]. Cur-
cumin has also shown potent activity against other organisms
including: Schistosoma mansoni adult worms, Cryptosporid-
ium parvum, and Trypanosoma cruzi [8–10].
Previous studies have shown that a combination of oral
curcumin and intramuscular administration of artemisi-
nin derivative 𝛼-𝛽 arteether to P. berghei-infected mice
improved the survival rates and prevented recrudescence [6].
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In contrast, a previous work done by our group [7] has
shown that oral administration of 300mg/kg of body weight
(bw) of curcumin in combination with 20mg/kg/bw of
piperine and 150mg/kg of artemisinin showed no conclusive
effect on the course of infection [7]. However, antimalarial
activity and peak parasitemia reached by the curcumin and
curcumin/piperine treatment groups were significantly lower
compared to the control untreated group [7].
It is not clear what the targets of curcumin are. Some
authors have suggested that the target of curcumin might be
similar to that which initially was thought to be the target of
artemisinin (PfATP6) [11]; however, a recent study has shown
that the targets of artemisinin remain unclear [12]. Others
have shown that curcumin might be an inhibitor of histone
acetyltransferase (HAT) and it can also induce the production
of reactive oxygen species which may contribute to para-
site’s death [13]. However, a recent study has shown that
curcumin may interfere with many signaling pathways [14]
including: the mitogen-activated protein kinases (MAPKs),
casein kinase II (CKII), and the COP9 signalosome (CSN) as
well as the ubiquitin proteosome pathway (UPS) which will
be analyzed in this study [14].
An in silico study [15] has shown that the genome of
Plasmodium spp. contains several genes encoding proteins
predicted to be involved in the UPS [15]. Ubiquitylation
is a regulated posttranslational modification of proteins in
which an ubiquitin molecule is attached to a lysine amino
acid in the target protein [15, 16]. Attachment of ubiquitin
molecules to proteins is catalyzed by the action of ubiquitin
activating enzymes (E1), ubiquitin-conjugating enzyme (E2),
and ubiquitin ligase (E3) [15, 16]. In general, ubiquitylation
linked via Lys29 or Lys48 with four or more ubiquitin
molecules is targeted for degradation by the proteasome [17,
18]. On the other hand, ubiquitylation linked via Lys63 on
the target protein is involved in the regulation of a myriad
of cellular processes [17, 18].
The removal of ubiquitin molecules is carried out by de-
ubiquitylating enzymes (DUBs) [15–19], which are respon-
sible for the generation of free ubiquitin molecules and the
disassembly of mono- or polyubiquitin chains on substrate
proteins [15–19].The Plasmodium genome encodes at least 20
to 40 putative DUBs [15–19] which are classified as cysteine
proteases and zinc-dependent metalloproteases based on
their ubiquitin protease domain [15–19]; these are: the ubiq-
uitin C terminal hydrolases (UCHs), the ubiquitin specific
proteases (USP/UBPs), theMachado—Joseph disease protein
domain proteases (MJDs), the Otubains (OTUs), the JAMM
motif metalloproteases (JAMMs), and the permuted papain
fold peptidase (PPPDE) as well as [15–19] deubiquitylating-
like enzymes (DUBLs), which have been thoroughly reviewed
by others [15–19].
It has become apparent that deubiquitylation plays an
important role in the regulation of the UPS as confirmed
by aberrations in genes encoding DUBs [20]. Furthermore,
DUBs have also been implicated in antimalarial drug resis-
tance as confirmed by mutations found in a gene encoding
a de-ubiquitylating enzyme UBP-1 (MAL1P1.34b) in Plas-
modium chabaudi parasites resistant to artemisinin and arte-
sunate [21]. The V2697F and V2728F mutations lie close to
the catalytic site of the enzyme and probably affect protein
structure and function [21]. However, the role of those
mutations in artemisinin drug resistance is yet to be clarified
through transfection assays [21]. Taken together this data
shows that the UPS represents a promising antimalarial drug
target [22].
The aim of the present study was to analyze the effi-
cacy and the drug interactions between curcucmin/piperine/
chloroquine and curcumin/piperine/artemisinin in Plasmod-
ium chabaudi parasites resistant to chloroquine (AS-3CQ)
and artemisinin (AS-ART) and to verify the effects of cur-
cumin, chloroquine, and artemisinin drug treatment on the
UPS.
2. Materials and Method
2.1. Plasmodium chabaudi Parasite Clones. Plasmodium
chabaudi clones available in our database and used in this
study were AS-3CQ (resistant to chloroquine) and selected
from the clone AS-Pyr which was subjected to six daily
doses of chloroquine (CQ) at 3mg/kg [23]. This parasite line
was cloned and named AS-3CQ [23]. The AS-ART clone
resistant to artemisinin was obtained from a clone known
as AS-30CQ which tolerated 300mg/kg/day of artemisinin
[24] obtained by serial passages in the presence of increasing
subcurative doses of artemisinin [23, 24]; this parasitic line
was cloned and named AS-ART [24]. The clones displayed
a stable phenotype even after freezing/thawing serial blood
passages through mice in the absence or presence of drug
treatment, and transmission through the mosquito vector
Anopheles stephensi.
2.2. Acute Toxicity of Curcumin. BALB/cmalemice weighing
15 g and 6-7 weeks old were purchased from the animal
house facility at the IHMT (Institute of Hygiene & Tropical
Medicine, Lisbon, Portugal). The LD50 of curcumin in
BALB/c mice was determined by oral administration of five
doses 2 g/kg/bw; 2,5 g/kg/bw; 3 g/kg/bw; 3,5 g/kg/bw; and
5 g/kg/bw to each individualmouse after four hours of fasting.
Five grams is the concentration reported by others [27, 28]
to be the highest dose known to be administered to mice for
the acute toxicity test of any drug. Animals were observed for
14 days for any physical signs of toxicity including trembling,
lethargic behavior, and impaired body movements.
2.3. In Vivo Four-Day Suppressive Test of Curcumin, Cur-
cumin/Piperine, Curcumin/Piperine/Chloroquine, and Cur-
cumin/Piperine/Artemisinin. In the present study the in vivo
efficacy and the interaction of curcumin/piperine in combi-
nation with artemisinin and chloroquine was assayed using
the 4-day suppressive test [29]. Curcumin 94% cucuminoid
content (Sigma-Aldrich, Madrid, Spain) and artemisinin
(Sigma-Aldrich, Madrid, Spain) were dissolved in DMSO
(Sigma-Aldrich, Madrid, Spain) and chloroquine (Sigma-
Aldrich, Madrid, Spain) was dissolved in water. The parasites
kept in liquid nitrogenwere thawed andmicewere inoculated
with 1 × 106 infected red blood cells. Parasitemia was allowed
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to evolve and once parasitemia reached 30%, infected blood
was collected and diluted with citrate saline solution.
An intraperitoneal injection of 1 × 106 infected red blood
cells was administered to individual mice. Cages contained
a maximum of 5 mice each and were kept in a light-
dark cycle and mice had food and water ad libitum. Three
hours later mice were administered by oral gavage either
chloroquine alone, curcumin alone, or the combination
of curcumin/piperine/chloroquine as piperine 97% (Sigma-
Aldrich,Madrid, Spain) has been reported in a previous study
to have no antimalarial activity [7], but it is reported to
enhance curcumin uptake [30].
The same procedure was carried out in mice infected
with AS-ART resistant parasites. Infected mice received an
inoculum of 1 × 106 infected red blood cells and three
hours later groups of 5 mice per cage were administered an
oral dose of artemisinin alone, curcumin alone, and cur-
cumin/piperine, and another group received a combination
of curcumin/piperine/artemisinin. All experiments included
a drug-free control group. Drugs were administered orally
for 4 days (Day 0, 1, 2, 3). Parasitemia was monitored every
day following drug treatment for a period of 7 consecutive
days, as previous work has shown that differences in cur-
cumin/piperine combination versus the control group can
be observed between 5 and 7 days after drug treatment had
ended [7]. Thin blood smears were prepared and stained
with 20% Giemsa/PBS solution (Sigma-Aldrich, Madrid,
Spain) pH 7.2, and microscopic slides were analyzed by light
microscopy.
2.4. In Vivo Drug Interaction Studies and Isobolograms. The
ED50 values (the concentration that produces 50% reduction
of parasitemia) of the drug alone and in combination were
calculated by plotting the log dose versus relative percentage
inhibition using GraphPad Prism 4 Software (GraphPad
Prism4,CA,USA) using nonlinear regression, dose-response
curve according to the 4-parameter logistic equation (Hill
slope). From the ED50 and the Hill slope the ED90 values
were calculated using the formula LogED50 = LogED90 −
(1/Hill Slope) × log(9) and the equation 𝑌 = Bottom +
(Top−Bottom)/(1+10∧((LogED50-X)×Hill slope)) [25]. In
order to generate isobolograms [25] the ED90 values of the
drug combination and the drug alone were calculated from
the linear equation of the dose-response curve of the drug
alone and in combination 7 days after treatment had ended.
The ED90 values were then used to calculate the isobolar
equivalent (IE) values [25, 26]. Isobolograms were designed
to include a diagonal line (black solid) which represents the
line of additivity (Figures 2 and 4). Isobolograms allowed the
visualization of additivity, synergism, or antagonism. If the
IE values are below 1 it produces an isobologram that skews
below the additivity line indicating synergism [25, 26]. When
the IE values are equal or close to 1 most values will lie closely
to the additivity line indicating additivity. If most IE values
are above 1, this indicates antagonism [25, 26].
2.5. Statistical Analysis. A student t-test and the ANOVA
test were used for statistical analysis using GraphPad Prism
4 software and SPSS software version 9.0 USA. All exper-
iments were carried out according to the guidelines of the
animal facility of the Institute of Hygiene and Tropical
Medicine (IHMT), Lisbon, Portugal and according to the
FELASA guidelines.
2.6. Expression Profile of Genes Encoding Enzymes of the
Ubiquitin/Proteasome Pathway in P. chabaudi. As previously
mentioned curcumin is known to interfere with the UPS
[14]. This was verified here by RT-PCR. In this study we
selected three genes encoding deubiquitylating enzymes and
the sequences were retrieved from the PlasmoDB database
and used for primer design (Table 2).The human homologue
of PcUCH-L3 regulates the apical membrane recycling of
epithelial sodium channels [31]. The human homologue of
PcUCH-L5 appears to be associated with the proteosome and
possibly involved in TG𝛽 signaling [19]. UBP-8 gene in yeast
regulates transcription mechanisms and it is responsible for
the deubiquitylation of histone H2B [32]. Given the impor-
tance of these genes in other biological systems, we analyzed
the basal expression of these genes in P. chabaudi throughout
the parasite’s life cycle and their response to treatment with
subtherapeutic doses of chloroquine (2mg/kg), artemisinin
(2mg/kg), and curcumin (2mg/kg).
2.7. Plasmodium chabaudi RNA Extraction and cDNA Syn-
thesis. Plasmodium chabaudi-infected red blood cells were
collected at time point 0 h; a microscopy analysis revealed
that the parasites present were mainly young tropho-
zoites. Infected red blood cells were passed through a
column of fibrous cellulose powder (CF11) (Sigma-Aldrich,
Madrid, Spain) to remove lymphocytes. The resulting solu-
tion was centrifuged at 700 g for 5 minutes and RNA was
extracted from the obtained pellet using Trizol (Sigma-
Aldrich, Madrid, Spain) and following the manufacturer’s
instructions. RNA (1 𝜇g) was mixed with 5𝜇L of DNase I
buffer and 1 𝜇L of DNase I (Promega, Mannheim, Germany)
and incubated at 37∘C for 15mins. DNaseI was inactivated
by adding 1 𝜇L of EDTA (Promega, Mannheim, Germany)
and incubated at 65∘C for 5min. RNA (50 ng) previously
treated with DNase I was used as template and was mixed
with the Maxima first strand cDNA synthesis kit for RT-PCR
(Fermentas, Madrid, Spain) and water to a final volume of
25 𝜇L according to the manufacturer’s instructions. Samples
were incubated for 10min at 25∘C, followed by 30min at
50∘C and the reaction of cDNA synthesis was terminated by
incubation at 85∘C for 5min.
2.8. Real-Time PCR Analysis of P. chabaudi Genes Encoding
Deubiquitylating Enzymes and RT-PCR Conditions. Real-
time PCR using the IQ SYBR green supermix (Bio-RAD,
Lisbon, Portugal) was carried out using microAmp 96-well
plates (Applied Biosystems,Madrid, Spain) in triplicates with
a 25 𝜇L final volume containing IQ SYBRgreen supermix dye,
0.025U/𝜇L iTaq DNA polymerase (Promega, Mannheim,





































































































































































































































Figure 1: Parasitamia evolution in mice infected with P. chabaudi clone AS-3CQ treated with: chloroquine, curcumin, curcumin/piperine,
and curcumin/piperine/chloroquine. Drugs were administered by oral gavage for 4 consecutive days and parasitemia was followed every
day following drug treatment for 7 consecutive days. Results represent the mean parasitemia ± S.D. #Significant difference (𝑃 < 0.05) was
found between the curcumin/piperine treatment group versus the curcumin only treatment group. ∗Significant difference (𝑃 < 0.05) was
found between curcumin/piperine/chloroquine group versus the curcumin only treatment group, curcumin/piperine treatment group, and
chloroquine only treatment group (2.5mg/kg).
and each individualmixture contained 300 nMof the forward
primer (StabVida, Lisbon, Portugal) and 300 nM (StabVida,
Lisbon, Portugal) of the reverse primers specific for PcUCH-
L3, PcUCH-L5, and PcUBP-8; finally, 2 𝜇L of cDNA diluted
1 : 10 obtained from infected mice treated with curcumin,
chloroquine, and artemisinin were added to each individual
mixture.
The reaction was performed under the following amplifi-
cation conditions: 10min of preincubation at 95∘C, followed
by 40 cycles for 15 seconds at 95∘C and 1min at 60∘C
in a 7500 fast RT-PCR thermocycler (Applied Biosystems,
Madrid, Spain). Primers designed against P. chabaudi Pc𝛽-
actinI gene (Pc𝛽-actinI) were used as the endogenous control
as previously reported by others [33]. In order to determine
PCR efficiencies for each individual gene, samples were
diluted in serial 10-fold ranges, and the CT value at each dilu-
tion was measured.
A curve was then constructed for each gene from which
efficiency was determined. Real-time PCR efficiencies (𝐸)
were calculated from given slopes according to the equation:
𝐸 = 10(−1/slope), where 𝐸 = 2 corresponds to 100% effi-
ciency [34].
2.9. Analysis of Relative Expression Using the 2−ΔΔ𝐶𝑇 Method.
The 2−ΔΔCT method was used to calculate the relative quan-
tification of target gene [34]. The purpose was to analyze first
the expression of the studied genes throughout the parasite’s
life cycle, in the absence of any kind of treatment.The second
aim was to analyze the differences in expression of each
studied gene in parasites exposed to drug treatment versus
a sample collected at time 0 h which was not exposed to
drug treatment. Differences in N-fold expression compared
to the untreated sample were analyzed using a student t-test
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Figure 2: Isobologram illustrating the in vivo interaction at
the ED90 level between drug A (curcumin-piperine) with drug
B (chloroquine) in Plasmodium chabaudi AS-3CQ chloroquine-
resistant parasites. Plotting the percentage parasitemia inhibition
versus the log dose of the drugs either alone and the drugs in
combination using GraphPad Prism 4 software yielded a regression
equation. The equation allowed the determination of the ED90 of
the drugs alone and the drugs in combination. ED90 values were
used to obtain isobolar equivalents (IE) [25, 26].
Table 1: Acute toxicity test for curcumin. Mice were allowed to
fast 4 hours. After 4 hours a single dose of curcumin was orally
administered in different concentrations to BALB/c infected mice.
Mice were observed for 14 days for any physical signs of toxicity.
LD50 cytotoxicity test Weight Survival (days)
2,0 g per kg of body weight 15 g 14 days
2,5 per kg of body weight 15 g 10 days
3,0 g per kg of body weight 15 g 5 days
3,5 g per kg of body weight 15 g 3 days
5,0 g per kg of body weight 15 g 1 day
𝑃 ≤ 0.05 (𝑛 = 3 assays) performed in GraphPad Prism 4
Software and SPSS software version 9.0.
3. Results
3.1. In Vivo Efficacy and Drug Interaction Studies of Cur-
cumin Alone and Curcumin/Piperine/Chloroquine and Cur-
cumin/Piperine/Artemisinin Drug Combinations. Given the
emergence of artemisinin combination therapy (ACT), drug
resistance new antimalarials are urgently needed. The aim of
this study was to determine the in vivo efficacy of curcumin
alone or in combination: curcumin/piperine/chloroquine
and curcumin/piperine/artemisinin in order to clarify their
drug interactions in Plasmodium chabaudi resistant parasites.
The acute toxicity studies revealed that curcumin was
nontoxic to mice even at 2 g/kg/bw (Table 1); mice survived
for 14 days with no signs of toxicity. The results show that
curcumin alone was able to delay peak parasitemia in a dose-
dependent manner (Figures 1 and 3) in both P. chabaudi
clones. Statistically, there was no significant difference (𝑃 >
0.05) between the control untreated group and the groups
treated with 50mg and 150mg curcumin alone. Significant
results were observed especially at 500mg/kg/bw where
parasitemia dropped to 47% in the AS-3CQ clone and 45% in
the AS-ART clone compared to the control untreated group
(𝑃 = 0.003) 65% and 62% (Figures 1 and 3).
Curcumin combined with piperine showed a mild anti-
malarial effect which is in agreement with previous work [7].
Again in both clones curcumin/piperine combination was
more efficient at reducing parasitemia at higher doses. At
250mg curcumin + 20mg of piperine parasitemia dropped
to 45% inmice infected with the chloroquine resistance clone
(AS-3CQ) and 44% in mice infected with the artemisinin
resistance clone (AS-ART) relative to the control (𝑃 =
0.04) (Figure 3). When curcumin at 500mg was combined
with 20mg of piperine parasitemia dropped to 42% in mice
infected with the chloroquine-resistant parasite line and 40%
in mice infected with the artemisinin-resistant parasite line
with𝑃 value significant (𝑃 = 0.02), indicating that the efficacy
of the curcumin/piperine combination in P. chabaudi clones
was also in a dose-dependent manner. For the drug inter-
action studies four doses of chloroquine were administered
orally tomice infectedwith the chloroquine-resistant parasite
line (AS-3CQ) and of the 4 doses given 2,5mg of chloroquine
was found to reduce parasitemia to 48% after 7 days post
drug treatment. AS-3CQ parasites were treated with 5mg/kg
and 10mg/kg which reduced parasitemia to 15% and 9%,
respectively. Hence a choice was made not to combine these
higher doses with curcumin/piperine as they wouldmask the
effect of the combination.
When curcumin/piperine was combined with a fixed
dose of 2,5mg/kg of chloroquine, parasitemia reduction was
better than when curcumin was used either alone or when
it was used in combination with piperine (Figure 1). When
curcumin/piperine/chloroquine was administered to mice a
significant reduction in parasitemia was achieved compared
to the control group. This reduction was even more evident
at higher doses (150mg + 20mg + 2,5mg) parasitemia 45%
(𝑃 = 0.033), (250mg + 20mg + 2,5mg) parasitemia 39%
(𝑃 = 0.01), and (500mg + 20mg + 2,5mg) parasitemia 37%
(𝑃 = 0.0001) relative to the control sample (Figure 1).
It is interesting to note that when curcumin/piperine/
chloroquine are combined together less curcumin is needed
to actually see a statistically significant suppression in para-
sitemia. This is evident as parasitemia dropped to 50% with
the combination (curc 50mg + pip 20mg + CQ 2,5mg)
(𝑃 < 0.03) compared to the control group 65%, indicating an
additive/weak synergistic effect which was confirmed by the
isobologram (Figure 2) with most values achieved below 1,5.
Although the interaction of curcumin/piperine/chloroquine
was favorable and helped to reduce the parasite load, a
followup of parasitemia for another 8 days (total 15 days)
showed that a complete clearance of parasites to submicro-
scopic levels was not achieved. There was always a residual
parasitemia of <2% detected in the slides. An indication
that the parasites did not lose their chloroquine-resistant
phenotype.
The group of mice infected with the artemisinin-resistant
parasite line AS-ART was also treated with four doses of
artemisinin alone (50mg, 150mg, 250mg, and 350mg) and
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Table 2: Oligonucleotide primers designed from the mRNA sequences retrieved from PlasmoDB.
Oligonucleotide primers Primer Sequence Amplicon size (bps)
Gene ID Gene















































































































































































































































Figure 3: Parasitemia evolution in mice infected with P. chabaudi clone AS-ART treated with: artemisinin, curcumin, curcumin/piperine,
and curcumin/piperine/artemisinin. Drugs were administered by oral gavage for 4 consecutive days and parasitemia was followed every
day following drug treatment for 7 consecutive days. Results represent the mean parasitemia ± S.D. #Significant difference was found
between the artemisinin only treatment group (150mg/kg) versus the curcumin, curcumin/piperine, and curcumin/piperine/artemisinin.
∗Significant difference was found (𝑃 < 0.05) between the curcumin/piperine group versus the curcumin only treatment group and the
curcumin/piperine/chloroquine.
at 350mg/kg of artemisinin alone parasitemia dropped to 5%
compared to the control group 67% (𝑃 = 0.0001) (Figure 3).
A decrease in parasitemiawas also observed at 50mg, 150mg,
and 250mg (Figure 3) and 150mg/kg was chosen as the dose
used to combine with curcumin/piperine (Figure 3).
Again treatment of Plasmodium chabaudi resistant AS-
ART parasite line with curcumin alone only resulted in a sig-
nificant parasitemia reduction at higher doses. At 500mg/kg
of curcumin parasitemia reduced to 45% (𝑃 = 0.0001)
compared to the control group 62% (Figure 3).This reduction
was even more evident when curcumin was combined with
piperine which resulted in a parasitemia reduction from 67%
to 40% (𝑃 = 0.0001) (Figure 3).
Addition of a fixed dose of 150mg/kg of artemisinin to
curcumin/piperine did not result in a clear difference in
parasitemia reduction between the control group and the
artemisinin/curcumin/piperine (𝑃 = 0.08) which is in agree-
ment with previous work [7]. In fact, even at higher doses
(curcumin 500mg + piperine 20mg + 150mg artemisinin)
parasitemia dropped to 50% relative to the control group
(𝑃 = 0.055) 62% (Figure 3).
It seems that curcumin, curcumin/piperine, and artemi-
sinin alone performed better separately as opposed to when
the three compounds are combined (Figure 4). The isobolo-
gram indicates that most values were bigger than 1,5 which
resulted in an isobologram where most of the values are far
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Figure 4: Isobologram illustrating the in vivo interaction at the
ED90 level between drug A (curcumin-piperine) with drug B
(artemisinin) in Plasmodium chabaudi AS-ART (artemisinin) resis-
tant parasites. Plotting the percentage parasitemia inhibition versus
the log dose of the drugs either alone and the drugs in combination
usingGraphPad Prism 4 Software yielded a regression equation.The
equation allowed the determination of the ED90 of the drugs alone
and the drugs in combination. ED90 values were used to obtain
isobolar equivalents (IE) [25, 26].
away from the additivity line, indicating antagonism amongst
the components of the drug combination.
3.2. Expression of the Genes PcUCH-L3, PcUCH-L5, and
PcUBP-8 in P. chabaudi Parasites and the Effects of Drug
Treatment on the Expression of Those Genes. Three genes
encoding de-ubiquitylating enzymes PcUCH-L3, PcUCH-L5,
and PcUBP-8 were analyzed by RT-PCR in the presence and
absence of drug treatment in order to verify whether drug
treatment interferes with the UPS. The results suggest that
in both clones AS-3CQ and AS-ART the three genes under
study are highly expressed at 6 h time point (Figures 5 and 6).
Microscopic slides prepared at that time point when mRNA
was collected revealedmost of the parasitesweremainly at the
mature trophozoite stage, which is the most replicative stage
of the parasite’s life [35], and statistically there is no difference
in the basal expression of the three genes between the two
clones (𝑃 = 0.08).
Treatment of AS-3CQ parasites with a subcurative single
dose of chloroquine and a subcurative single dose of cur-
cumin induced an increase in the expression of all three
genes (Figures 7 and 8) specially at 6 h and 12 h after drug
exposure, compared to the untreated sample collected at time
point 0 h (𝑃 = 0.002). Statistical analysis was also applied to
compare the basal expression of the genes at 6 h and 12 h time
points versus the same samples exposed to treatment, which
revealed a difference (𝑃 = 0.01). Microscopic slides analyzed
revealed mostly the presence of schizonts at 12 h time point,
which is also the stage of the parasite in which chloroquine
is known to act. The effects appear to be transient with all
genes returning to levels similar to the untreated sample 24
hours later. Microscopic slides revealed the presence of ring-
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Figure 5: Basal expression profile of the genes PcUCH-L3, PcUCH-
L5, and UBP-8 in the clone AS-3CQ. The results are expressed as
means and standard deviation of three independent experiments.
∗Indicates significant difference (𝑃 < 0.05) between the sample
collected at time point 0 h versus 6 h samples. Statistically no
significant (𝑃 > 0.05) difference was found between the samples
collected at time point 12 h and 24 h sample versus the 0 h sample.
PcUBP-8 was the gene that exhibited the highest increase in
expression relative to the untreated sample 0 h (𝑃 = 0.001)
(Figures 7 and 8).
In AS-ART parasites treated with a single subcurative
dose of artemisinin and a single subcurative dose of curcumin
there was also an increase in the expression of all three genes
relative to the untreated sample 0 h, which was more evident
at 6 h and 12 h following drug exposure (𝑃 = 0.002). In both
treatments PcUBP-8 was the gene that exhibited the highest
increase in N-fold expression relative to the control untreated
sample (𝑃 = 0.0001). The expression levels induced by drug
treatment were transient with the three genes returning to
levels similar to the untreated sample 0 h (Figures 9 and 10).
4. Discussion
Given the emergence of drug resistance against ACTs, new
alternatives for the treatment of malaria are urgently needed.
Curcumin has already shown great potential both in vitro
and in vivo against Plasmodium spp. [6, 7]. However, its
poor availability and rapidmetabolism are issues to overcome
in order to exploit the full benefits of this plant-derived
compound [36]. Enhancers such as piperine derived from
black pepper which is already known to improve the bioavail-
ability of curcumin [36] were hereby tested as a combina-
tion: curcumin/piperine/chloroquine and curcumin/piper-
ine/artemisinin.
The results show that the interaction between cur-
cumin/piperine/chloroquine was additive and helped in






















PcUCH-L3 basal  expression
PcUCH-L5 basal expression
PcUBP-8 basal expression










Figure 6: Basal expression profile of the genes PcUCH-L3, PcUCH-
L5, and UBP-8 in the clone AS-ART. The results are expressed as
means and standard deviation of three independent experiments.
∗Indicates significant difference between (𝑃 < 0.05) between the
sample collected at time point 0 h versus 6 h samples. Statistically
no significant (𝑃 > 0.05) difference was found between the samples












































Figure 7: Expression profile of the genes PcUCH-L3, PcUCH-
L5, and UBP-8 exposed to chloroquine treatment. The results are
expressed as means and standard deviation of three independent
experiments. ∗Indicates significant difference (𝑃 < 0.05) between
the sample collected at time point 0 h versus 6 h samples and the 12 h
sample. Statistically no significant (𝑃 > 0.05) difference was found
between the samples collected at time point 0 h versus 24 h sample.
the reduction of the parasite load 7 days after treatment had
ended. The results are interesting: although both drugs have
different structures and different modes of action, they both
have anti-inflammatory properties which possibly contribute
to parasitemia reduction [37]. Curcumin is well known for
its immunomodulatory properties which include: activation














































Figure 8: Expression profile of the genes PcUCH-L3, PcUCH-
L5, and UBP-8 exposed to curcumin treatment. The results are
expressed as means and standard deviation of three independent
experiments. ∗Indicates significant difference (𝑃 < 0.05) between
the sample collected at time point untreated 0 h versus 6 h samples
and the 12 h sample. Statistically no significant (𝑃 > 0.05) difference
was found between the samples collected at time point (0 h) versus
24 h sample.
antibodies [37]. Chloroquine is well known for its antimalar-
ial schizonticidal activity as well as its anti-inflammatory
properties such as inhibition of tumor necrosis factor-𝛼, IL-
1𝛽, and IL-6 [38] making both drug combinations interest-
ing in the treatment of other diseases where an excess of
proinflammatory cytokines is produced. It is believed that
curcumin is an attractive compound for adjunctive treat-
ment of cerebral malaria [39] which is often treated with
quinine, from which chloroquine derives. Hence further
pharmacokinetic studies between curcumin and quinine and
its derivatives are needed to exploit their potential in antima-
larial treatment.
The combination of curcumin/piperine/artemisinin did
not show a favourable drug interaction. Although it was
able to reduce parasitemia statistically there was no dif-
ference between the control untreated group and the cur-
cumin/piperine/artemisinin group. In fact the mice treated
with artemisinin alone and curcumin alone actually had a sig-
nificant reduction in parasitemia comparedwithmice treated
with the drug combination curcumin/piperine/artemisinin
(Figure 3).
An in vitro study carried out in P. falciparum revealed
synergism between curcumin and artemisinin, and the in
vivo assay where 𝛼,𝛽-arteether was injected intramuscularly
in P. berghei-infected mice followed by curcumin feeding
was able to prevent recrudescence [6]. However, in the
study mentioned piperine was not used as an enhancer and












































Figure 9: Expression profile of the genes PcUCH-L3, PcUCH-L5,
and UBP-8 in the clone AS-ART exposed to curcumin treatment.
The results are expressed as means and standard deviation of three
independent experiments. ∗Indicates significant difference (𝑃 <
0.05) between the sample collected at time point untreated 0 h versus
6 h samples and the 12 h sample. Statistically no significant (𝑃 >
0.05) was found between the samples collected at time point 0 h
versus 24 h sample.
the difference in the biology of P. chabaudi and P. berghei
parasites also needs to be taken into consideration. In the
present study the mixture of the three compounds admin-
istered orally resulted in an unfavorable pharmacodynamic
interaction. Recent studies in P. berghei-infected mice using
a combination of artemisinin and curcumin have also shown
that although parasites can be cleared from the blood, they
remain in the spleen and the liver [37], favoring recrudes-
cence.
Artemisinin has a half life of approximately 8–14 hours
[37] and curcumin has a half life of 8 h [37]. Studies carried
out in rats have reported that only about 0,1%–0,25%of piper-
ine administered orally can be detected in the liver whereas
intraperitoneal administration of piperine resulted in 1–2,5%
of piperine detection in the liver 6 hours later [40]. Given the
fact that the three drugs have different structures anddifferent
modes of action, clearly more studies are needed including
different administration routes and HPLC analysis of mice
tissue after treatment with curcumin/piperine/artemisinin in
order to clarify drug distribution and elimination.
Artemisinin derivatives as well as curcumin derivatives
might offer an alternative to the pure compound. A Study
has shown that the pyrazole analogue of curcumin (methyl
curcumin) has 7–9 fold activity against P. falciparum CQ-
sensitive and CQ-resistant strains with IC50 values of 0.48
and 0.45 𝜇M [41] compared to curcumin which has an in
vitro IC50 of 5 𝜇M [41]. Previous work has also shown
that artemisinin at 50mg/kg/bw combined with curcumin at
100mg/kg/bw encapsulated in conventional liposomes cured
all P. berghei malaria-infected mice when compared to free














































Figure 10: Expression profile of the genes PcUCH-L3, PcUCH-L5,
and UBP-8 in the clone AS-ART exposed to artemisinin treatment.
The results are expressed as means and standard deviation of three
independent experiments. ∗Indicates significant difference (𝑃 <
0.05) between the sample collected at time point 0 h versus 6 h
samples and the 12 h sample. Statistically no significant (𝑃 > 0.05)
difference was found between the samples collected at time point 0 h
versus 24 h sample.
as liposomes and nanoparticles may be the key in delivering
drugs with short half life and poor bioavailability [42]. It
has also been shown that curcumin when bound to chitosan
nanoparticles is able to completely cure P. yoelii infected
mice [43]. Hence future studies with curcumin should aim at
finding suitable drug-delivery systems [43] and better drug
partners in order to maximize the benefits of curcumin as an
antimalarial agent.
The gene expression assays showed evidence of an active
UPS in P. chabaudi parasites mainly at the trophozoite
stage which coincides with high metabolic activity, which is
necessary for parasite replication [35]. In the present study all
three drugs administered orally were able to induce transient
changes in the expression of the three genes with PcUBP-8
showing the highest increase when exposed to all three drugs
(Figures 7, 8, 9, and 10) relative to the untreated sample. As
mentioned previously, PcUBP-8 gene in yeast Saccharomyces
cerevisiae is required for optimal gene activation and is
responsible for the de-ubiquitylation of histone H2B, which
is involved in chromatin remodeling [32]. In P. chabaudi
parasites the role of PcUCH-L3, PcUCH-L5, and PcUBP-8
enzymes is unknown. It is not clear whether these enzymes
are controlling epigenetic mechanisms or regulating the
transcription of P. chabaudi genes. Previous work using serial
analyses of gene expression (SAGE) technique has shown
that in chloroquine-treated P. falciparum cultures a 5.5-fold
increase in a gene encoding an ubiquitin-specific protease
and a 5.5-fold increase in a gene encoding a proteosome
subunit 𝛼 were observed [44]. On the other hand, treatment
of human breast carcinoma MCF-7 cells with doxorubicin,
10 Journal of Parasitology Research
which also has antimalarial activity [45], showed an 18.6-fold
increase in the 26S proteosome regulatory subunit [46]
indicating that alterations in the UPSmay represent a general
adaptation of the parasite to drug treatment.
It is already known that drug treatment can interfere
with ion homeostasis, which would result in alterations in
the intracellular pH of several organelles that are crucial for
parasite survival, thereby interfering with enzyme activity
and function [47], which would explain the necessity of an
increase in the transcription and translation of PcUCH-L3,
PcUCH-L5, and PcUBP-8 gene products to compensate for
enzyme damage. Damaged proteins are likely to act as a
stimulus to induce the expression of genes encoding enzymes
involved in protein synthesis and protein degradation in
order to allow the parasite to cope with intracellular stress.
Hence, upregulation of the UPS in general would be needed
to help the parasite survive under drug pressure, which could
very well be a mechanism of defense and or resistance,
making the UPS an attractive drug target [48].
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